Literature DB >> 28704361

From Krebs to clinic: glutamine metabolism to cancer therapy.

Brian J Altman, Zachary E Stine, Chi V Dang.   

Abstract

Entities:  

Year:  2016        PMID： 28704361     DOI： 10.1038/nrc.2016.114

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  1 in total

Review 1.  From Krebs to clinic: glutamine metabolism to cancer therapy.

Authors:  Brian J Altman; Zachary E Stine; Chi V Dang
Journal:  Nat Rev Cancer       Date:  2016-07-29       Impact factor: 60.716
  1 in total
  82 in total

Review 1.  Microenvironmental Metabolism Regulates Antitumor Immunity.

Authors:  Verra M Ngwa; Deanna N Edwards; Mary Philip; Jin Chen
Journal:  Cancer Res       Date:  2019-07-30       Impact factor: 12.701

2.  Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations.

Authors:  Adeola O Adebayo Michael; Sungjin Ko; Junyan Tao; Akshata Moghe; Hong Yang; Meng Xu; Jacquelyn O Russell; Tirthadipa Pradhan-Sundd; Silvia Liu; Sucha Singh; Minakshi Poddar; Jayvir S Monga; Pin Liu; Michael Oertel; Sarangarajan Ranganathan; Aatur Singhi; Sandra Rebouissou; Jessica Zucman-Rossi; Silvia Ribback; Diego Calvisi; Natalia Qvartskhava; Boris Görg; Dieter Häussinger; Xin Chen; Satdarshan P Monga
Journal:  Cell Metab       Date:  2019-01-31       Impact factor: 27.287

3.  Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.

Authors:  Irfana Soomro; Ying Sun; Zhai Li; Lonnette Diggs; Georgia Hatzivassiliou; Ajit G Thomas; Rana Rais; Seth J Parker; Barbara S Slusher; Alec C Kimmelman; Stefan Somlo; Edward Y Skolnik
Journal:  Nephrol Dial Transplant       Date:  2018-08-01       Impact factor: 5.992

4.  Glutaminolysis is required for transforming growth factor-β1-induced myofibroblast differentiation and activation.

Authors:  Karen Bernard; Naomi J Logsdon; Gloria A Benavides; Yan Sanders; Jianhua Zhang; Victor M Darley-Usmar; Victor J Thannickal
Journal:  J Biol Chem       Date:  2017-12-08       Impact factor: 5.157

5.  Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.

Authors:  Suman Mukhopadhyay; Debanjan Goswami; Pavan P Adiseshaiah; William Burgan; Ming Yi; Theresa M Guerin; Serguei V Kozlov; Dwight V Nissley; Frank McCormick
Journal:  Cancer Res       Date:  2020-01-07       Impact factor: 12.701

6.  Metabolic Control over mTOR-Dependent Diapause-like State.

Authors:  Abdiasis M Hussein; Yuliang Wang; Julie Mathieu; Lilyana Margaretha; Chaozhong Song; Daniel C Jones; Christopher Cavanaugh; Jason W Miklas; Elisabeth Mahen; Megan R Showalter; Walter L Ruzzo; Oliver Fiehn; Carol B Ware; C Anthony Blau; Hannele Ruohola-Baker
Journal:  Dev Cell       Date:  2020-01-27       Impact factor: 12.270

Review 7.  The role of the glutamine transporter ASCT2 in antineoplastic therapy.

Authors:  Estefânia Teixeira; Cláudia Silva; Fátima Martel
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-19       Impact factor: 3.333

Review 8.  Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting.

Authors:  Y-R Yu; P-C Ho
Journal:  Clin Exp Immunol       Date:  2019-04-01       Impact factor: 4.330

9.  Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival.

Authors:  Venkatrao Vantaku; Sri Ramya Donepudi; Danthasinghe Waduge Badrajee Piyarathna; Chandra Sekhar Amara; Chandrashekar R Ambati; Wei Tang; Vasanta Putluri; Darshan S Chandrashekar; Sooryanarayana Varambally; Martha K Terris; Kimberly Davies; Stefan Ambs; Roni Bollag; Andrea B Apolo; Arun Sreekumar; Nagireddy Putluri
Journal:  Cancer       Date:  2019-01-02       Impact factor: 6.860

Review 10.  Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.

Authors:  Julieta Afonso; Lúcio L Santos; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  Nat Rev Urol       Date:  2020-01-17       Impact factor: 14.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.